Twist bioscience corp (TWST)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Cash flows from operating activities
Net loss

-146,503

-140,668

-107,669

-96,290

-85,998

-76,938

-71,236

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

6,140

6,144

6,111

5,951

6,061

5,913

5,727

0

0

0

Loss on disposal of property and equipment

-

-

-189

0

0

0

-

-

-

-

Non-cash lease expense

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

14,289

13,003

11,170

8,893

6,464

4,289

2,961

0

0

0

Discount accretion on investment securities

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

195

215

233

286

292

301

254

0

0

0

Change in fair value of redeemable convertible preferred stock warrant liability

-

-

-

-

-

-

-13

0

0

0

Amortization of debt discount

235

260

282

297

307

293

308

0

0

0

Changes in assets and liabilities:
Accounts receivable, net

6,833

6,076

6,685

7,238

3,982

3,955

3,073

0

0

0

Inventories

6,314

1,855

1,302

1,244

1,336

3,289

4,202

0

0

0

Prepaid expenses and other current assets

476

1,805

-746

1,086

1,999

2,216

1,760

0

0

0

Other non-current assets

2,069

1,610

2,064

-198

744

1,093

812

0

0

0

Accounts payable

2,220

3,437

3,278

2,124

435

2,090

3,759

0

0

0

Accrued expenses

515

2,892

4,210

1,329

474

587

-114

0

0

0

Accrued compensation

1,177

3,571

5,060

6,497

4,400

1,864

1,932

0

0

0

Accrued litigation settlement

-

0

-

-

-

-

-

-

-

-

Other liabilities

-595

-193

-247

-147

44

270

50

0

0

0

Net cash used in operating activities

-139,025

-101,167

-87,937

-81,275

-76,135

-71,832

-66,164

0

0

0

Cash flows from investing activities
Purchases of property and equipment

13,860

14,893

14,757

11,911

7,368

4,099

3,688

0

0

0

Purchases of investments

97,486

120,276

177,574

137,413

86,774

63,984

3,523

0

0

0

Proceeds from maturity of investments

0

0

-

-

-

-

34,500

0

0

0

Net cash provided by (used in) investing activities

17,275

-26,648

-104,810

-103,219

-75,933

-46,666

27,306

0

0

0

Cash flows from financing activities
Proceeds from exercise of stock options

4,986

3,624

2,170

1,149

294

409

331

0

0

0

Proceeds from public offering, net of underwriting discounts and commissions and offering expenses

272,631

85,453

156,208

0

0

0

-

-

-

-

Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

90,850

0

0

0

Payments of deferred offering costs

-

-

-

-

-

-

2,359

0

0

0

Repayments of long-term debt

0

0

-

-

-

-

-

-

-

-

Repurchases of common stock for income tax withholding

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

277,307

87,636

158,578

162,233

102,778

159,159

88,822

0

0

0

Effect of exchange rates on cash, cash equivalents and restricted cash

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

155,569

-40,140

-34,139

-22,261

-49,290

40,661

49,964

0

0

0

Supplemental disclosure of cash flow information
Interest paid

637

718

779

769

774

755

751

0

0

0

Income taxes paid, net of refunds

250

282

291

380

328

227

179

0

0

0

Non-cash investing and financing activities
Property and equipment additions included in accrued expenses and accounts payable

758

-881

170

0

0

0

-

-

0

0

Operating lease right-of-use assets obtained in exchange for operating lease liabilities

0

0

-

-

-

-

-

-

-

-

Offering expenses included in accounts payable and accrued expenses

-

-

-

-

1,288

2,047

1,308

0

0

0

Conversion of redeemable convertible preferred stock warrant liability to equity

-

-

631

0

0

0

-

-

-

-

Conversion of redeemable convertible preferred stock to common stock

-

-

290,462

0

0

0

-

-

-

-